recent
intern
epidem
coronavirusassoci
ill
underscor
urgent
medic
public
health
need
vaccin
develop
regulatori
bodi
approv
therapi
particular
current
coronaviru
diseas
pandem
quickli
intensifi
interest
develop
treatment
option
mitig
impact
human
life
remdesivir
broadspectrum
antivir
drug
test
potenti
treatment
intern
multisit
clinic
trial
current
avail
evid
antivir
effect
remdesivir
coronavirus
primarili
base
vitro
vivo
studi
includ
chemic
relat
compound
demonstr
larg
favor
find
pandem
progress
inform
human
compassion
use
case
continu
accumul
clinic
trial
conclud
imper
public
health
practition
one
health
commun
stay
date
promis
potenti
therapeut
option
investig
thu
purpos
review
synthes
knowledg
date
remdesivir
therapeut
option
coronavirus
special
focu
inform
relev
one
health
commun
first
human
coronavirus
hcov
identifi
major
past
six
decad
hcov
gener
maintain
rel
innocu
reput
caus
common
cold
howev
public
percept
awar
hcov
shift
consider
last
twenti
year
onset
three
high
profil
outbreak
garner
intern
attent
subsequ
led
renew
interest
potenti
therapeut
option
hcovrel
ill
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
peopl
reach
countri
result
case
fatal
rate
year
april
novemb
laboratoryconfirm
case
infect
middl
east
respiratori
syndrom
coronaviru
merscov
reach
countri
mortal
rate
approxim
though
serolog
studi
impli
preval
merscov
may
underestim
recent
emerg
sever
acut
respiratori
syndrom
coronaviru
decemb
wuhan
subsequ
spread
countri
across
world
gener
intens
interest
vaccin
develop
treatment
option
coronaviru
diseas
remdesivir
fig
investig
broadspectrum
smallmolecul
antivir
drug
demonstr
activ
rna
virus
sever
famili
includ
coronavirida
sarscov
merscov
strain
bat
coronavirus
capabl
infect
human
respiratori
epitheli
cell
paramyxovirida
nipah
viru
respiratori
syncyti
viru
hendra
viru
filovirida
ebola
viru
origin
develop
treat
ebola
viru
infect
remdesivir
prodrug
parent
adenosin
analog
fig
metabol
activ
nucleosid
triphosph
ntp
host
fig
parent
nucleosid
display
antivir
activ
sarscov
marburg
viru
felin
infecti
periton
viru
among
other
number
studi
examin
effect
two
drug
coronavirus
cov
vitro
vivo
use
mous
nonhuman
primat
anim
model
current
antivir
drug
approv
treatment
covspecif
ill
given
rapidli
evolv
pandem
crucial
public
health
practition
one
health
commun
stay
date
potenti
therapeut
option
investig
base
exist
data
remdesivir
fig
promis
candid
multisit
clinic
trial
remdesivir
underway
among
hospit
adult
review
summar
knowledg
date
remdesivir
therapeut
option
cov
virus
classifi
coronavirida
famili
envelop
positivesens
singlestrand
rna
virus
exhibit
high
genet
divers
within
orthocoronavirina
subfamili
four
genera
alphacoronaviru
betacoronaviru
gammacoronaviru
deltacoronaviru
virus
famili
infect
wide
varieti
host
speci
bird
human
nonhuman
mammal
includ
dromedari
camel
alpaca
domest
pig
dog
cat
ferret
mink
bat
howev
knowledg
virus
alphaand
betacoronaviru
genera
infect
human
though
gammaand
deltacoronaviru
genera
indirect
effect
econom
impact
agricultur
product
poultri
pig
host
specif
believ
larg
depend
upon
variat
cov
spike
attach
glycoprotein
although
infect
strain
host
speciesspecif
host
rang
wide
across
differ
cov
bat
cov
reli
host
receptor
angiotensinconvert
human
cov
facilit
entri
cell
hypothes
cov
propens
hostswitch
may
partli
attribut
recombin
event
alter
spike
protein
turn
affect
interact
host
receptor
eg
histor
hcov
larg
consid
rel
low
virul
virus
produc
less
sever
selflimit
diseas
predominantli
known
second
preval
caus
cold
upper
respiratori
infect
uri
rhinovirus
endem
human
cov
cumul
account
uri
alphacoronavirus
betacoronavirus
among
patient
uri
sever
enough
warrant
hospit
one
studi
found
approxim
case
attribut
rhinovirus
hcov
substanti
proport
hospit
patient
underli
pulmonari
cardiac
comorbid
may
exacerb
condit
viru
underli
betacoronaviru
close
relat
sarscov
cov
rna
sequenc
ident
similar
even
greater
virus
compar
sequenc
specif
key
drug
target
rnadepend
rna
polymeras
rdrp
sequenc
ident
contrast
merscov
share
genom
sequenc
ident
except
bat
strain
mani
anim
cov
even
less
similar
nucleosid
analog
remdesivir
act
rdrp
inhibitor
target
viral
genom
replic
process
rdrp
protein
complex
cov
use
replic
rnabas
genom
host
metabol
remdesivir
activ
ntp
metabolit
compet
adenosin
triphosph
atp
natur
nucleotid
normal
use
process
incorpor
nascent
rna
strand
incorpor
substitut
new
strand
result
prematur
termin
rna
synthesi
halt
growth
rna
strand
nucleotid
ad
although
cov
proofread
process
abl
detect
remov
nucleosid
analog
render
resist
mani
drug
remdesivir
seem
outpac
viral
proofread
activ
thu
maintain
antivir
activ
unsurprisingli
agostini
et
al
report
mutant
murin
hepat
viru
mhv
devoid
proofread
abil
sensit
remdesivir
opposit
also
possiblethat
mutat
improv
proofread
otherwis
increas
fidel
basepair
process
may
result
remdesivir
resist
fact
agostini
et
al
also
induc
mutat
mhv
passag
remdesivir
confer
strong
resist
drug
mutat
strain
outcompet
wildtyp
mhv
coinfect
cell
cultur
expos
remdesivir
well
experi
would
repres
situat
resist
mutat
develop
natur
though
unclear
nonetheless
evid
suggest
remdesivir
could
addit
mechan
action
yet
discov
true
may
allow
partial
antivir
activ
continu
despit
viral
mutat
enhanc
replic
fidel
exist
studi
potenti
antivir
effect
remdesivir
highest
relev
viru
underli
current
pandem
conduct
genet
similar
coronavirus
discuss
within
coronavirida
famili
virus
substanti
amount
genet
heterogen
even
among
human
strain
genet
divers
posit
attribut
larg
viral
genom
molecular
nuanc
viral
rna
replic
process
eg
rdrp
infidel
although
remdesivir
broadspectrum
antivir
efficaci
famili
virus
may
generaliz
effect
attempt
predict
level
potenti
generaliz
hamper
possibl
drug
may
secondari
mechan
action
yet
elucid
result
review
focus
studi
effect
remdesivir
cov
specif
howev
inform
research
lesser
relat
virus
eg
ebola
briefli
mention
addit
context
drug
major
vitro
efficaci
studi
conduct
date
report
posit
result
anticov
activ
remdesivir
tabl
commonli
use
metric
studi
half
maxim
effect
concentr
ec
drug
concentr
half
maximum
respons
attain
exposur
half
maxim
inhibitori
concentr
ic
drug
concentr
half
peak
inhibit
effect
drug
specif
viral
function
achiev
lower
ec
ic
valu
indic
higher
potenc
typic
outcom
measur
studi
includ
amount
viral
rna
eg
copi
certain
open
read
frame
cultur
number
virusinfect
cell
cultur
chang
viral
replic
rate
studi
sarscov
merscov
human
respiratori
epitheli
cell
cultur
remdesivir
demonstr
strong
antivir
activ
ec
either
viru
rel
consist
shown
capabl
inhibit
merscov
replic
level
would
result
unaccept
cytotox
interestingli
studi
publish
februari
wang
et
al
first
knowledg
examin
effect
remdesivir
hcov
involv
current
pandem
studi
investig
impact
seven
differ
drug
viral
titer
cytotox
infect
rate
use
vero
cell
cell
line
origin
african
green
monkey
kidney
epitheli
cell
found
low
potenc
drug
inhibit
ec
valu
rang
wide
ribavirin
choloquin
remdesivir
two
drug
requir
lowest
concentr
block
viral
infect
vitro
studi
also
investig
util
remdesivir
nonhuman
cov
exampl
studi
murphi
et
al
report
anticov
activ
remdesivir
parent
nucleosid
alphacoronaviru
infect
wild
domest
cat
felin
infecti
periton
fip
viru
ec
tabl
brown
et
al
observ
antivir
effect
remdesivir
sarslik
bat
cov
specif
batcov
batcov
batcov
merslik
bat
cov
specif
batcov
studi
detect
weaker
antivir
effect
porcin
deltacoronaviru
pdcov
tabl
particularli
test
porcin
cell
line
among
current
known
cov
pdcov
least
similar
rdrp
sequenc
compar
sarscov
merscov
similar
amino
acid
sequenc
fact
rdrp
pdcov
differ
amino
acid
specif
site
phenylalanin
leucin
residu
dissimilar
previous
associ
increas
resist
remdesivir
cov
therefor
import
attempt
disentangl
whether
lower
antivir
activ
observ
could
relat
viral
characterist
pdcov
could
attribut
differ
cell
line
use
diminish
potenc
remdesivir
pdcov
note
cultur
porcin
kidney
epitheli
cell
human
liver
cell
line
ec
rel
low
ec
reach
vs
ec
tabl
similarli
ec
substanti
higher
antivir
activ
endem
hcov
porcin
cell
line
compar
indic
like
lower
potenc
drug
context
thu
observ
variat
remdesivir
potenc
virus
differ
cell
line
may
impli
factor
associ
cell
line
rather
viru
may
affect
drug
antivir
activ
fact
author
state
find
may
impli
cell
lack
cellular
process
necessari
remdesivir
antivir
activ
could
also
support
hypothesi
remdesivir
may
anoth
mechan
action
present
understood
anim
studi
remdesivir
efficaci
cov
util
transgen
mice
rhesu
macaqu
exampl
use
mous
model
better
emul
human
metabol
remdesivir
compar
wildtyp
mice
human
merscov
receptor
sheahan
et
al
found
prophylact
therapeut
remdesivir
protect
effect
merscov
replic
associ
patholog
gener
result
less
lung
damag
better
pulmonari
function
compar
control
interestingli
among
mice
infect
higher
viru
quantiti
ie
plaqueform
unit
receiv
prophylact
remdesivir
one
day
infect
significantli
better
surviv
infect
control
mice
receiv
remdesivir
howev
mice
sacrif
longer
followup
data
could
obtain
similarli
rhesu
macaqu
model
merscov
pathogenesi
prophylact
therapeut
administr
remdesivir
demonstr
favor
result
reduc
respiratori
tract
viral
titer
pulmonari
patholog
prophylact
use
initi
h
prior
viral
challeng
wherea
therapeut
use
initi
h
challeng
respiratori
rate
substanti
differ
prophylact
therapeut
control
group
xray
score
repres
sever
pulmonari
infiltr
significantli
better
prophylact
therapeut
group
compar
control
incident
remdesivir
also
associ
benefici
effect
includ
reduc
sever
respiratori
sign
improv
surviv
challeng
nipah
viru
noncov
viru
paramyxovirida
famili
african
green
monkey
mous
model
sarscov
infect
prophylact
therapeut
remdesivir
treatment
result
lower
lung
viral
titer
therapi
administ
day
postinfect
peak
viral
replic
associ
greater
pulmonari
function
compar
control
howev
differ
diseas
patholog
surviv
treatment
administ
day
postinfect
veterinari
studi
also
examin
effect
parent
nucleosid
cat
fip
condit
associ
high
mortal
cat
gilead
scienc
foster
citi
california
provid
drug
research
univers
california
davi
evalu
potenti
util
veterinari
indic
subsequ
becam
intermedi
product
prodrug
remdesivir
superior
abil
transport
activ
compound
cell
drug
yield
activ
metabolit
host
cell
prior
studi
antivir
activ
remdesivir
also
investig
andor
discuss
relev
veterinari
studi
murphi
et
al
examin
efficaci
fip
experiment
infect
cat
control
includ
histor
data
untreat
cat
avail
demonstr
mortal
rate
close
experiment
challeng
fip
viru
cat
develop
fiprel
sign
remain
untreat
infect
cat
treatment
initi
upon
onset
fipassoci
clinic
sign
day
post
infect
continu
week
cat
half
n
treat
mgkg
dose
administ
subcutan
per
day
half
n
treat
mgkg
daili
diseas
recur
initi
treatment
cat
retreat
use
regimen
anoth
week
followup
continu
month
treat
cat
demonstr
favor
respons
treatment
within
h
regardless
dose
still
aliv
clinic
unremark
month
post
infect
two
cat
one
dose
group
experienc
diseas
recurr
week
week
initi
treatment
retreat
advers
event
relat
treatment
temporari
discomfort
inject
site
observ
studi
base
small
number
anim
unclear
whether
experiment
infect
relev
represent
naturallyoccur
fipv
infect
cat
futur
studi
addit
followup
time
would
help
assess
whether
unexpect
longterm
sequela
observ
cat
sinc
inform
surviv
anim
spars
given
high
fatal
rate
field
trial
treatment
natur
occur
fip
pedersen
et
al
treat
cat
initi
dose
mgkg
daili
within
first
week
treatment
cat
sever
diseas
die
euthan
fifth
cat
die
day
anoth
euthan
post
relaps
due
develop
neurolog
sign
lack
respons
treatment
remain
cat
complet
least
week
treatment
experienc
relaps
requir
retreat
dose
escal
mgkg
mgkg
daili
requir
cat
total
treat
cat
surviv
fip
least
week
follow
indic
presum
prodrug
remdesivir
also
promis
therapeut
candid
treatment
alphacoronavirusrel
diseas
cat
cat
studi
wet
effus
fip
hallmark
accumul
fluid
abdomin
thorac
caviti
cat
studi
abdomin
noneffus
dri
fip
chronic
condit
anoth
cat
initi
dri
fip
progress
wet
fip
one
cat
dri
fip
group
one
drytowet
group
surviv
small
number
cat
dri
fip
conclus
drawn
whether
remdesivir
greater
efficaci
treatment
clinic
manifest
fip
other
strength
studi
conduct
among
anim
naturallyoccur
cov
infect
field
trial
better
repres
realworld
circumst
first
patient
present
us
treat
intraven
remdesivir
compassion
use
claus
develop
pneumonia
januari
male
infect
travel
wuhan
return
us
hospit
day
treat
intraven
remdesivir
seventh
day
condit
reportedli
improv
eighth
day
advers
event
relat
remdesivir
use
note
case
report
written
prior
patient
discharg
human
data
remdesivir
use
like
continu
becom
avail
compassion
use
case
clinic
trial
complet
fact
mani
anecdot
report
alreadi
circul
treatment
patient
remdesivir
accord
recent
newspap
articl
passeng
diamond
princess
cruis
ship
treat
intraven
remdesivir
day
aliv
time
articl
releas
one
physician
involv
treatment
affili
us
nation
institut
health
nih
felt
patient
less
depend
ventil
receiv
drug
nevertheless
conclus
drawn
base
report
preprint
case
seri
first
patient
us
diseas
onset
januari
recent
becam
avail
though
peerreview
time
write
report
author
team
center
diseas
control
cdc
describ
demograph
clinic
characterist
patient
well
inform
cours
diseas
clinic
manag
seven
patient
hospit
three
patient
receiv
remdesivir
intraven
onset
worsen
symptom
two
eleventh
day
ill
one
seventh
day
treatment
remdesivir
toler
though
temporari
gastrointestin
upset
elev
aminotransferas
level
observ
three
patient
administr
treatment
discontinu
respiratori
symptom
improv
total
treatment
durat
day
day
day
note
one
three
patient
patient
describ
case
report
discuss
safeti
data
formal
collect
clinic
trial
conduct
democrat
republ
congo
random
patient
treat
remdesivir
ebola
incident
random
remdesivir
treatment
discontinu
trial
interim
analysi
show
superior
surviv
two
trial
drug
despit
preclin
compassion
use
data
favor
remdesivir
ebola
viru
prior
trial
interestingli
patient
receiv
remdesivir
slower
rate
viral
clearanc
compar
patient
receiv
singledos
antivir
specif
author
hypothes
may
relat
fact
treatment
plan
remdesivir
involv
multipl
intraven
infus
howev
inform
potenti
efficaci
remdesivir
specif
cov
larg
limit
vitro
anim
studi
though
relat
knowledg
evolv
quickli
overal
past
studi
cov
may
limit
generaliz
viru
underli
current
pandem
high
genet
divers
coronavirida
famili
although
broadspectrum
drug
tend
direct
wellconserv
target
addit
issu
number
factor
impact
predict
find
vitro
vivo
model
may
clinic
efficaci
exampl
drug
may
effect
vitro
may
clinic
util
therapeut
dose
induc
sever
advers
event
patient
altern
treatment
dose
attain
effect
serum
concentr
patient
ec
greater
achiev
maximum
serum
concentr
c
max
drug
less
like
therapeut
util
regard
anim
model
close
model
repres
diseas
pathogenesi
drug
metabol
human
challeng
gaug
multipl
clinic
trial
underway
use
remdesivir
treatment
nihsponsor
clinic
trial
ongo
us
republ
korea
doubleblind
placebocontrol
trial
patient
random
receiv
either
placebo
initi
dose
mg
intraven
remdesivir
first
day
follow
mainten
dose
mg
per
day
discharg
maximum
total
treatment
day
primari
outcom
trial
describ
us
nation
librari
medicin
clinic
trial
registri
express
proport
patient
categori
sevencategori
clinic
sever
scale
fifteenth
day
post
treatment
initi
tabl
addit
gilead
scienc
sponsor
remdesivir
studi
among
patient
sever
composit
primari
outcom
measur
fever
normal
oxygen
normal
hospit
invas
mechan
ventil
extracorpor
membran
oxygen
hospit
noninvas
ventil
high
flow
oxygen
devic
hospit
requir
supplement
oxygen
hospit
requir
supplement
oxygen
hospit
limit
activ
hospit
limit
activ
pleas
note
inform
taken
verbatim
us
nation
librari
medicin
clinic
trial
registri
es
amirian
jk
levi
one
health
two
doubleblind
placebocontrol
trial
also
recruit
hubei
provinc
china
one
target
hospit
patient
mildtomoder
focus
sever
case
primari
outcom
measur
studi
mild
moder
case
time
clinic
recoveri
defin
normal
bodi
temperatur
respiratori
rate
oxygen
satur
resolut
cough
least
h
studi
sever
case
time
clinic
improv
primari
outcom
defin
use
sixcategori
scale
rang
discharg
death
previou
studi
remdesivir
promis
formal
clinic
evalu
strongli
warrant
gener
mani
reason
favor
preclin
data
fail
translat
directli
human
clinic
trial
result
inadvert
use
irrelev
model
inabl
achiev
effect
serum
drug
concentr
patient
occurr
unanticip
sever
advers
event
among
patient
therefor
postul
expect
result
trial
extrem
challeng
nonetheless
hundr
clinic
trial
ongo
intern
differ
drug
util
variou
mechan
action
includ
trial
nucleosid
inhibitor
eg
ribavirin
proteas
inhibitor
eg
lopinavirritonavir
receptor
inhibitor
eg
sarilumab
anoth
wellknown
candid
evalu
multipl
trial
chloroquin
hydroxychloroquin
alreadi
approv
antimalari
extraintestin
amebiasi
result
clinic
trial
current
underway
us
china
provid
crucial
inform
whether
remdesivir
repres
viabl
treatment
option
trial
find
ultim
posit
imper
ensur
drug
produc
commerci
scale
capabl
meet
demand
gener
current
pandem
futur
outbreak
chang
product
may
also
allow
ad
benefit
drug
becom
avail
agricultur
veterinari
use
relev
indic
work
receiv
specif
grant
fund
agenc
public
commerci
notforprofit
sector
author
report
relev
conflict
interest
es
amirian
previous
employ
mckesson
specialti
health
conduct
health
econom
outcom
research
contract
studi
howev
none
studi
involv
gilead
scienc
